Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ocular Symptom Can Be the First Presentation of Differentiation Syndrome in Acute Promyelocytic Leukemia

11 Dec 2020

Abstract excerpt

Acute promyelocytic leukemia (APL) is a subtype of acute myelocytic leukemia, characterized by the chromosomal abnormality t(15:17) coding a PML/RAR alpha fusion protein that affects differentiation of the promyelocyte cell in bone marrow. All-trans retinoic acid (ATRA), a key treatment for APL, acts as a differentiating agent in combination with other induction chemotherapy. Differentiation syndrome (DS) is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Drug-Induced Ocular Toxicity
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33307628
DOI: 10.3341/kjo.2020.0101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ocular Symptom Can Be the First Presentation of Differentiation Syndrome in Acute Promyelocytic LeukemiaPMID 33307628Read ↗

Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndromeSemantic proximity Read ↗

Acute promyelocytic leukemia (APL): a review of the literatureSemantic proximity Read ↗

Acute Promyelocytic Leukemia: Pathophysiology, Diagnosis and Clinical ManagementSemantic proximity Read ↗

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factorsSemantic proximity Read ↗

Clinical Manifestations and Ophthalmic Outcomes of Leukemic Retinopathy and Optic Neuropathy in Patients With Acute Leukemia.Semantic proximity Read ↗

Early Complications in the Era of ATRA Plus ATO Therapy Outside of Clinical Trials‐One Center Experience during Three Years and Literature Review‐Semantic proximity Read ↗

Classic and Variants APLs, as Viewed from a Therapy ResponseSemantic proximity Read ↗

Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia – the occurrence of retinoic acid syndrome is a risk factorSemantic proximity Read ↗

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectivesSemantic proximity Read ↗

How retinoic acid and arsenic transformed acute promyelocytic leukemia therapySemantic proximity Read ↗

Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemiaSemantic proximity Read ↗

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.